No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest that guggulsterone activates PXR and therefore has the potential to induce CYP3A4 metabolism. No effect on emtricitabine or tenofovir-DF is expected as they do not undergo CYP3A4 metabolism.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking